| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $5,630 | 8 | 100 |
| Saccomano Nicholas A | President and CEO | 0 | $0 | 4 | $1,252 | $-1,252 |
| Leverone Jason A. | Chief Financial Officer | 0 | $0 | 4 | $4,378 | $-4,378 |
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Over the last 12 months, insiders at OnKure Therapeutics, Inc. have bought $0 and sold $5,630 worth of OnKure Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at OnKure Therapeutics, Inc. have bought $2.59M and sold $1.72M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,400,000 shares for transaction amount of $2.59M was made by ACORN BIOVENTURES, L.P. (10 percent owner) on 2025‑05‑15.
| 2026-09-21 | Sale | Leverone Jason A. | Chief Financial Officer | 302 0.0008% | $2.97 | $898 | -16.99% | |
| 2026-09-21 | Sale | Saccomano Nicholas A | President and CEO | 87 0.0002% | $2.97 | $259 | -16.99% | |
| 2026-06-22 | Sale | Leverone Jason A. | Chief Financial Officer | 303 0.0022% | $4.40 | $1,332 | -14.53% | |
| 2026-06-22 | Sale | Saccomano Nicholas A | President and CEO | 86 0.0006% | $4.40 | $378 | -14.53% | |
| 2026-03-23 | Sale | Leverone Jason A. | Chief Financial Officer | 301 0.0023% | $4.16 | $1,251 | +2.26% | |
| 2026-03-23 | Sale | Saccomano Nicholas A | President and CEO | 86 0.0007% | $4.16 | $357 | +2.26% | |
| 2025-12-22 | Sale | Leverone Jason A. | Chief Financial Officer | 302 0.0023% | $2.97 | $896 | +27.70% | |
| 2025-12-22 | Sale | Saccomano Nicholas A | President and CEO | 87 0.0007% | $2.97 | $258 | +27.70% | |
| 2025-09-22 | Sale | Leverone Jason A. | Chief Financial Officer | 303 0.002% | $2.62 | $795 | +29.89% | |
| 2025-09-22 | Sale | Saccomano Nicholas A | President and CEO | 88 0.0006% | $2.62 | $231 | +29.89% | |
| 2025-06-23 | Sale | Leverone Jason A. | Chief Financial Officer | 303 0.0018% | $2.38 | $722 | +21.58% | |
| 2025-06-23 | Sale | Saccomano Nicholas A | President and CEO | 88 0.0005% | $2.38 | $210 | +21.58% | |
| 2025-05-15 | Sale | Cormorant Asset Management, LP | Former 10% Owner | 1.81M 8.5595% | $1.85 | $3.36M | +37.38% | |
| 2025-05-15 | ACORN BIOVENTURES, L.P. | 10 percent owner | 1.4M 6.592% | $1.85 | $2.59M | +37.38% | ||
| 2025-05-12 | Sale | Cormorant Asset Management, LP | 10 percent owner | 24,300 0.1228% | $1.99 | $48,236 | +44.62% | |
| 2025-04-07 | Sale | Leverone Jason A. | Chief Financial Officer | 1,844 0.0125% | $2.67 | $4,925 | -11.00% | |
| 2025-04-07 | Sale | Saccomano Nicholas A | President and CEO | 516 0.0035% | $2.67 | $1,378 | -11.00% | |
| 2025-04-04 | Sale | Leverone Jason A. | Chief Financial Officer | 1,278 0.0108% | $3.33 | $4,253 | -12.14% | |
| 2025-04-04 | Sale | Saccomano Nicholas A | President and CEO | 358 0.003% | $3.33 | $1,191 | -12.14% |
| ACORN BIOVENTURES, L.P. | 10 percent owner | 1709944 4.2225% | $4.27M | 1 | 0 | +37.38% |
$5,552,811 | 165 | 5.84% | $106.2M | |
$1,701,941 | 56 | 17.58% | $93.09M | |
$66,137,559 | 49 | 6.29% | $89.66M | |
$77,146,704 | 43 | 13.28% | $93.12M | |
$130,095 | 43 | 45.19% | $111.24M |
| Increased Positions | 18 | +33.96% | 3M | +26.01% |
| Decreased Positions | 21 | -39.62% | 2M | -17.83% |
| New Positions | 8 | New | 2M | New |
| Sold Out Positions | 6 | Sold Out | 121,355 | Sold Out |
| Total Postitions | 50 | -5.66% | 11M | +8.18% |